Multitarget Directed Ligand Approaches for Alzheimer's Disease: A Comprehensive Review
Natarajan Ramalakshmi1, Remya R S1, Nalini C N2
1Department of Pharmaceutical Chemistry, C.L.Baid Metha College of Pharmacy, The Tamilnadu Dr. M.G.R. Medical University, Chennai, India.
Mini Reviews in Medicinal Chemistry
|April 6, 2021
Summary
Developing drugs for Alzheimer's disease (AD) requires targeting multiple factors, as single-target treatments have proven insufficient. This review explores multitarget approaches for discovering effective Alzheimer's disease therapies.
Area of Science:
- Neuroscience
- Pharmacology
- Drug Discovery
Background:
- Alzheimer's disease (AD) is a complex neurodegenerative disorder with no current cure, necessitating novel therapeutic strategies.
- Existing AD treatments offer only symptomatic relief, highlighting the limitations of single-target drug approaches.
- The multifactorial nature of AD and the ineffectiveness of current single-target drugs drive the development of multitarget directed ligands (MTDLs).
Purpose of the Study:
- To review multitarget approaches and tools for identifying lead compounds or new drugs for Alzheimer's disease.
- To explore recent advances in the discovery of novel therapeutic agents for AD.
Main Methods:
- A comprehensive review of 75 research articles published in peer-reviewed journals over the past two decades.
- Focus on multitarget directed ligand approaches for Alzheimer's disease drug discovery.
Main Results:
- The field of Alzheimer's disease research is actively pursuing effective treatments.
- Despite ongoing efforts, Alzheimer's disease remains incurable, with current treatments being palliative.
- Multitarget directed ligand strategies represent a promising avenue for developing novel therapeutic agents.
Conclusions:
- This review provides valuable insights for researchers developing multitarget directed ligands against Alzheimer's disease.
- The findings underscore the continued need for innovative research in AD therapeutics.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
532
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
532
01:26Alzheimer's Disease: Overview
1.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.0K
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
3.2K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
3.2K
01:19Ligand-gated Ion Channels
13.4K
Ligand-gated ion channels are transmembrane proteins with a channel for ions to pass through and a binding site for a ligand. The channel opens only when a ligand attaches to the binding site.
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that...
Three Subfamilies of Ligand-gated Ion Channels
Ligand-gated ion channels fall into three subfamilies. The 'Cys-loop' includes the nicotinic acetylcholine receptors, γ-aminobutyric acid (GABA), glycine, and 5-hydroxytryptamine receptors. The second one is the 'Pore-loop' channels that...
13.4K
01:30Dementia
276
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
276
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
291
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
291